Shanghai HeartCare Medical Technology First Half 2024 Earnings: CN¥0.14 loss per share (vs CN¥1.43 loss in 1H 2023)

Shanghai HeartCare Medical Technology (HKG:6609) First Half 2024 Results

Key Financial Results

• Revenue: CN¥128.5m (up 17% from 1H 2023).
• Net loss: CN¥5.12m (loss narrowed by 91% from 1H 2023).
• CN¥0.14 loss per share (improved from CN¥1.43 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai HeartCare Medical Technology Earnings Insights

Looking ahead, revenue is forecast to grow 1.8% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 23% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Shanghai HeartCare Medical Technology that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.